FDA approves BMY's (NYSE: BMY) Cobenfy, the first new schizophrenia drug in decades. While challenges include high costs and dosing, analysts project peak global sales of $4.9B by 2034. AbbVie and Neurocrine Biosciences are developing similar next-generation treatments.
